References

Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

Byrgazov, Konstantin¹; Besse, Andrej²; Kraus, Marianne²; Slipicevic, Ana¹; Lehmann, Fredrik¹; Driessen, Christoph²; Besse, Lenka²       Hemasphere. 2021 Jul; 5(7): e602. Oncopeptides AB, Stockholm, Sweden

CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

Min C., Moore N., Shearstone J., Quayle S., Huang P., van Duzer J., Jarpe M., Jones S., and Yang M. PLOS One. 2017; 12(1): e0169128. 2017 Jan 1.  Acetylon Pharmaceuticals Inc., Boston, MA, United States of America

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

• Chengyin Min , Nathan Moore, Jeffrey R. Shearstone, Steven N. Quayle, Pengyu Huang, John H. van Duzer, Matthew B. Jarpe, Simon S. Jones , Min Yang Acetylon Pharmaceuticals, Boston, MA

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2

Shearstone J., Golonzhka O., Chonkar A., Tamang D., van Duzer J., Jones S., and Jarpe M. PLoS One. 2016; 11(4): e0153767. 2016 April 4. Acetylon Pharmaceuticals Inc., Boston, MA, United States of America

A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation

Ferguson G.,¹,* Delgado M.,² Plantevin-Krenitsky V.,² Jensen-Pergakes K.,⁵ Bates R.,¹ Torres S.,¹ Celeridad M.,¹ Brown H.,³ Burnett K.,³ Nadolny L.,² Tehrani L.,² Packard G.,² Pagarigan B.,⁴ Haelewyn J.,⁴ Nguyen T.,⁴ Xu L.,¹ Tang Y.,³ Hickman M.,⁴ Baculi F.,⁴ Pierce S.,⁴ Miyazawa K.,⁶ Jackson P.,⁴ Chamberlain P.,⁴ LeBrun L.,⁴ Xie W.,¹ Bennett B.,¹ and Blease K. ³  PLoS One. 2016; 11(1): e0145705. 2016 Jan 12. Department of Inflammation Research, Celgene Corporation, San Diego, CA, United States of America

A Novel Microtubule Inhibitor 4SC-207 with Anti-Proliferative Activity in Taxane-Resistant Cells

Bausch E.,¹ Kohlhof H.,² Hamm S.,³ Krauss R.,² Baumgartner R.,² Sironi L.,¹ PLOS one, 8(11): 1-14, November 2013. ¹ Department of Biology and Konstanz Research School Chemical Biology, University of Konstanz, Konstanz, Germany, ² 4SC AG, Planegg – Martinsried, Germany, ³ 4SC Discovery GmbH, Planegg, Martinsried, Germany.

Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-D-2’-Deoxy-2’-α-Fluoro-2’-β-C-Methylguanosine

Lam A.,¹ Espiritu C.,¹ Murakami E.,¹ Zennou V.,¹ Bansal S.,¹ Micolochick Steuer H.M.,¹ Niu, C.,¹ Keilman M.,¹ Bao H.,¹ Bourne N.,² Veselenak R.L.,² Reddy P.G.,¹ Chang W.,¹ Du J.,¹ Nagarathnam D.,¹ Sofia M.J.,¹ Otto M.J.,¹ Furman P.A.,¹ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6): 2566–2575, June 2011. ¹Pharmasset, Inc., Princeton, NJ, ²University of Texas Medical Branch, Galveston, TX.

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661

Furman P.A.,¹ Murakami E.,¹ Niu C.,¹ Lam A.M.,¹ Espiritu C.,¹ Bansal S.,¹ Bao H.,¹ Tolstykh T.,¹ Micolochick Steuer H.,¹ Keilman M.,¹ Zennou V.,¹ Bourne N., ² Veselenak R.L.,² Chang W.,¹ Ross B.S.,¹ Du J.,¹ Otto M.J.,¹ Sofia M.J.,¹ Antiviral Research, 91: 120–132, 2011. ¹Pharmasset, Inc., East Princeton, NJ, USA, ²University of Texas Medical Branch, Galveston, TX, USA.

PSI-7851, a Pronucleotide of β-ᴅ-2’-Deoxy-2’-Fluoro-2’-C-Methyluridine Monophosphate, Is a Potent and Pan Genotype Inhibitor of Hepatitis C Virus Replication

Lam A.M.,¹ Murakami E.,¹ Espiritu C.,¹ Micolochick Steuer H.M,¹ Niu C.,¹ Keilman M.,¹ Bao H.,¹ Zennou V.,¹ Bourne N.,² Julander J.G.,³ Morrey J.D.,³ Smee D.F.,³ Frick D.N.,⁴ Heck J.A.,⁴ Wang P.,¹ Nagarathnam D.,¹ Ross B.S.,¹ Sofia M.J.,¹ Otto M.J.,^?1 Furman P.A.,¹ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8): 3187–3196, Aug 2010. ¹Pharmasset, Inc., Princeton, NJ; ²University of Texas Medical Branch, Galveston,TX; ³Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT; ⁴Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY.

Discovery of a β-ᴅ-2’-Deoxy-2’-α-fluoro-2’-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

Sofia M.J.,¹ Bao D.,¹ Chang W.,¹ Du J.,¹ Nagarathnam D.,¹ Rachakonda S.,¹ Reddy P.G.,¹ Ross B.S.,¹ Wang P.,¹ Zhang H.,¹ Bansal S.,¹ Espiritu C.,¹ Keilman M.,¹ Lam A.M.,¹ Micolochick-Steuer H.M.,¹ Niu C.,¹ Otto M.J.,¹ Furman P.A.,¹ J. Med. Chem., 53: 7202–721, 2010.  ¹Pharmasset, Inc., Princeton, NJ.

Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach

Maier M.,¹ Toxicology Mechanisms and Methods, 21(2): 76–85, 2011. ¹Cambrex Corporation, Charles City, IA, USA.

MP-470, a Novel Multi-Targeted Tyrosine Kinae Inhibitor Targeting Rad 51 is Not Toxic to Human Primary Marrow Stem Cells at Clinically Relevant Concentrations

Joshi R.,¹ Kanekal S.,¹ Redkar S.,¹ Berk G.,¹ 20^th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2008, Poster Abstract No. 480 . ¹Supergen Inc., Dublin, CA, USA.